Purchased Shares of Fuel Cell

The fund has purchased shares of Fuel Cell Energy. We purchased the shares for $1.93. We do not have a plan to sell the shares.

Fuel Cell Energy has a mission of  "Delivering clean innovative solutions for the global supply, recovery and storage of energy.".

We are excited to own shares of this company as it is providing an innovative, tested, valuable process that can help with climate change.  We believe the new management is starting to execute on its plans. They have strong partners both domestically, and internationally. The market is wide open with opportunity. 




**All posts on this blog are information and opinions only. They are not to be considered recommendations to buy or sell any security. Please do your due diligence first before trading and investing. Please direct all questions and comments to the blog, kdkfund@gmail.com, or on twitter @kdkfund.
 

Sold Remaining Microvision Shares

With some surprise, Microvision's stock price hit our target. With another opportunity staring at us, we have decided to sell the remaining shares at $0.94. The total profit for the 2 months the shares were held was over 300%. This was not expected.

Proceeds will go to taxes, KeaneVCC charity, investors and the rest will be put back into the account.


   **All posts on this blog are information and opinions only. They are not to be considered recommendations to buy or sell any security. Please do your due diligence first before trading and investing. Please direct all questions and comments to the blog, kdkfund@gmail.com, or on twitter @kdkfund.

Portfolio Weekly Performance (Crispr, Microvision, Hive Blockchain, Social Capital)

Here are some metrics and some activity notes.

Security/Project	Type	Date of Purchase	Cost of Investment	Current Value	Return %	Notes
Crispr Therapeutics	Stock	3/23/2020	$38.78	54.01	39.27%
Microvision	Stock	3/23/2020	$0.00	0.44	100.00%	Sold Cost portion. All Profit at this point
Hive Blockchain	Stock	4/16/2020	$0.16	0.23	43.75%
Social Capital	Stock	5/1/2020	$10.20	10.19	-0.10%

- Crispr released earnings this past week. Story link can be found here.
- Sold 1/2 of Microvision stock. Story here.
- Microvision releasing earnings this week. 
- Bought Social Capital. Story here. 



 **All posts on this blog are information and opinions only. They are not to be considered recommendations to buy or sell any security. Please do your due diligence first before trading and investing. Please direct all questions and comments to the blog, kdkfund@gmail.com, or on twitter @kdkfund.

New Position in Social Capital

A new position has been started in Social Capital (symbol IPOB.U). The fund paid $10.20 for each unit. There is no plan to sell the stake and a strong motivation to keep adding to the position.

Social Capital's mission is "to advance humanity by solving the world’s hardest problems". Who doesn't like that mission ;)? In some seriousness, they are a driven company with an exceptional CEO (Samath Palihapitiya). The market value of the companies they invest in have yet to be quantified. KDK Fund expects this stake to keep producing positive results (financial and otherwise) for decades to come.  Their website can be found here.


**All posts on this blog are information and opinions only. They are not to be considered recommendations to buy or sell any security. Please do your due diligence first before trading and investing. Please direct all questions and comments to the blog, kdkfund@gmail.com, or on twitter @kdkfund.

1/2 Position in Microvision Sold

The fund has sold 1/2 of its position in Microvision. Some of the reasons are below.

- The price of Microvision rose to $0.40.
- Selling 1/2 the position protects capital, leaving the rest as profit
- There are other opportunities for the capital



**All posts on this blog are information and opinions only. They are not to be considered recommendations to buy or sell any security. Please do your due diligence first before trading and investing. Please direct all questions and comments to the blog, kdkfund@gmail.com, or on twitter @kdkfund.

Portfolio Performance (Crispr, Microvision, Hive Blockchain)

Here are some metrics and notes on the portfolio. The portfolio reflects the performance of the resources available executing the mission of KDK Fund.  

Security/Project	Type of Investment	Date of Investment Purchase	Cost of Investment	Current Value of Investment	Return %
Crispr Therapeutics	Stock	3/23/2020	$38.78	54.01	39.27%
Microvision	Stock	3/23/2020	$0.18	0.25	38.89%
Hive Blockchain	Stock	4/16/2020	$0.16	0.23	43.75%

Week's Notes

- Crispr Therapeutics - will likely be announcing earnings on April 27th.

- Hive Blockchain - Bitcoin halving in May 2020 (definition of halvening through Gemini Capital found here).

- Microvision - Company shareholder meeting on May 19th, 2020 (link here).

- The fund will continue to look for opportunities to improve the fund. The next likely entry into the portfolio will be energy related.


**All posts on this blog are information and opinions only. They are not to be considered recommendations to buy or sell any security. Please do your due diligence first before trading and investing. Please direct all questions and comments to the blog, kdkfund@gmail.com, or on twitter @kdkfund.

Hive Blockchain Added to Portfolio

Hive Blockchain shares have been added to the portfolio.We currently feel that with the current resources available, this is the right move to be in the blockchain space. Hive Blockchain has the management experience, the existence in a growing market, and access to resources needed to build wealth for its stakeholders. The plan is to hold and likely add shares to the portfolio going forward. 

From the company's website - Simply put, HIVE is a cryptocurrency mining firm. We validate transactions on blockchain networks — like Ethereum — for rewards paid in cryptocurrencies. Everyday HIVE earns new crypto coins which it can monetize for revenue and cash flow. HIVE offers shareholders exposure to the operating margins from cryptocurrency mining plus a growing portfolio of coins.


KDK Fund looks to provide capital (financial, consulting, etc.) resources to companies and projects it deems are improving life's existence. The portfolio also has an equity stake in Crispr Therapeutics (post here), and Microvision (post here).  


 **All posts on this blog are information and opinions only. They are not to be considered recommendations to buy or sell any security. Please do your due diligence first before trading and investing. Please direct all questions and comments to the blog, kdkfund@gmail.com, or on twitter @kdkfund.